<DOC>
	<DOCNO>NCT00641667</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy fentanyl one-day transdermal patch ( patch contain drug put skin drug enter body skin ) participant switch morphine preparation , oral oxycodone preparation , fentanyl citrate injection fentanyl patch cancer pain .</brief_summary>
	<brief_title>An Efficacy Safety Study Fentanyl ( JNS020QD ) Participants With Cancer Pain</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( conducted one center ) non-comparative study fentanyl one-day transdermal patch . The study consist 3 period : Pre-treatment observation period ( 4-7 day ) , Treatment period ( 10 day ) Follow-up period ( 2 day ) . Treatment initiate 12.5 microgram per hour ( mcg/hr ) initial dose fentanyl determine base daily dose opioid analgesic take participant enter study maintain 2 day ensure safety participant . Dose escalation reduction per Investigator 's discretion Day 3 Day 7 thereafter dose maintain Day 7 Day 9 , range 12.5 mcg/hr-100 mcg/hr maximum application dose 300 mcg/hr . The patch apply area include chest , abdomen , upper arm thigh replace daily 10 day ( total 9 application ; include day final patch removal ) . Efficacy primarily evaluate visual analog scale ( VAS ) score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Participants receive follow drug stable dose least 3 day ( 9 day case fentanyl patch ) start application study drug : Morphine preparation less equal 314 milligram per day ( mg/day ) oral morphine equivalent dose less equal 157 mg/day suppository less equal 104 mg/day injection , oral oxycodone preparation less equal 209 mg/day , fentanyl citrate injection less equal 2.0 mg/day , fentanyl patch less equal 7.5 mg Participants assume use 2 rescue dos ( dose fastacting opioid analgesic except fentanyl preparation use lack analgesic effect ) daily least 3 day start application study drug Participants show pain intensity less equal 34 millimeter ( mm ) 100mm visual analog scale ( VAS ) Participants establish diagnosis cancer notify disease Participants hospitalize course application study drug Participants impaired respiratory function due chronic lung disease others Participants asthma ( breathe disorder wheeze difficulty breathe participant bradyarrhythmia ( slow , irregular heartbeat ) Participants follow measurement indicative hepatic renal impairment pretreatment observation period : Aspartate transaminase ( AST ) great 5 time upper limit reference range , Alanine transaminase ( ALT ) great 5 time upper limit reference range , serum creatinine great 3 time upper limit reference range Participants cerebral damage , brain tumor , accompany increase intracranial pressure , disturbance consciousness , coma , respiratory disturbance Participants history hypersensitivity fentanyl opioid analgesic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>JNS020QD</keyword>
</DOC>